A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol
Study Details
Study Description
Brief Summary
To compare the efficacy and safety profiles of Beclomethasone dipropionate Inhalation Aerosol, 40 mcg (test product) and QVAR 40 mcg (beclomethasone dipropionate HFA), Inhalation Aerosol (reference product) and to demonstrate that the efficacy of the 2 active products is superior to that of placebo in the treatment of subjects with asthma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Test Product Test Product, 40 mcg, 2 x daily |
Drug: Test Product
Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
|
| Active Comparator: Reference Product Reference Product, 40 mcg, 2 x daily |
Drug: Reference Product
QVAR® 40 mcg (Beclomethasone Dipropionate HFA)
Other Names:
|
| Placebo Comparator: Placebo Placebo Product 2 x daily |
Drug: Placebo
Placebo Product
|
Outcome Measures
Primary Outcome Measures
- Baseline-adjusted, pre-dose FEV1 on the last day of the 4-week treatment period [4 weeks]
FEV1 measured in the morning prior dosing of inhaled medications on the last day of the 4-week treatment. The primary endpoint should be baseline adjusted (change from baseline).
Other Outcome Measures
- Number and type of adverse events [Minimum of a 2-week run-in period followed by a 4-week treatment period]
To investigate the safety and tolerability of Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol in the target population.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult male or female subjects of non-childbearing or of childbearing potential committing to consistent and correct use of an acceptable method of birth control.
-
Diagnosis of asthma as defined by the National Asthma Education and Prevention Program at least 12 months prior to screening.
-
Pre-bronchodilator FEV1 of >45% and <85% of predicted value during the screening visit and on the first day of treatment.
-
15% and >0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI).
-
Patients should be stable on their chronic asthma treatment regimen for at least four weeks prior to enrollment.
-
Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having had <10 pack-years of historical use.
-
Ability to replace current short-acting β agonist (SABAs) with salbutamol/albuterol inhaler for use as needed for the duration of the study. Subjects should be able to withhold all inhaled SABAs for at least six hours prior to lung function assessments on study visits.
-
Ability to discontinue their asthma medications (inhaled corticosteroids and long-acting β agonists) during the run-in period and for remainder of the study.
-
Willingness to give their written informed consent to participate in the study.
Exclusion Criteria:
-
Life-threatening asthma, defined as a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma related syncopal episode(s), or hospitalizations within the past year prior to the screening or during the run-in period.
-
Significant respiratory disease other than asthma (COPD, interstitial lung disease, etc.)
-
Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study.
-
Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle ear infection within four weeks prior to the screening, during the run-in period, or on the day of treatment.
-
Hypersensitivity to any sympathomimetic drug (e.g., albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy.
-
Patients receiving β2-blockers, anti-arrhythmics, anti-depressants, and monoamine oxidase inhibitors within 4 weeks prior to the screening.
-
Patients who required systemic corticosteroids (for any reason) within the past 2 months.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beach Clinical Research, Inc. | Huntington Beach | California | United States | 92647 |
| 2 | Downtown La Research Center | Los Angeles | California | United States | 90017 |
| 3 | Moonshine Research Center | Doral | Florida | United States | 33166 |
| 4 | San Marcus Research Clinic, Inc. | Miami Lakes | Florida | United States | 33014 |
| 5 | Hope Clinical Trials, Inc. | Miami | Florida | United States | 33165 |
| 6 | Advanced Research for Health Improvement | Naples | Florida | United States | 34102 |
| 7 | Florida Institute for Clinical Research | Orlando | Florida | United States | 32825 |
| 8 | Innovation Research Center | Palmetto Bay | Florida | United States | 33157 |
| 9 | Florida Premier Research Institute | Winter Park | Florida | United States | 32789 |
| 10 | Monroe BioMedical Research | Monroe | North Carolina | United States | 28112 |
| 11 | TTS Research | Boerne | Texas | United States | 78006 |
| 12 | PCP for Life/ Mercury Clinical Research | Splendora | Texas | United States | 77372 |
Sponsors and Collaborators
- Amneal Ireland Limited
Investigators
- Study Director: Irshad Haque, Amneal Pharmaceuticals, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AI-BDP-001